NasdaqGS:ALNYBiotechs
How Alnylam’s Swing to Quarterly Profitability Could Reshape the Outlook for Alnylam Pharmaceuticals (ALNY) Investors
In the past quarter, Alnylam Pharmaceuticals reported first-quarter 2026 results showing revenue of US$1,167.18 million versus US$594.19 million a year earlier, with net income of US$205.99 million replacing a prior net loss and basic earnings per share rising to US$1.55 from a loss per share of US$0.14.
This sharp move into profitability, alongside improved earnings per share metrics, signals a meaningful shift in Alnylam’s operating profile that could influence how investors assess its...